BHST vs SIGA vs NVAX vs GILD vs MRNA

For growth investors, BioHarvest Sciences Inc.

Common Stock (BHST) is the stronger pick with 98. 8% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate BioHarvest Sciences Inc. Common Stock (BHST) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Gilead Sciences, Inc. at 19. 8x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gilead Sciences, Inc.

(GILD) is the lower-risk stock at 0. 66β versus Novavax, Inc. 's 2. 11β — meaning NVAX is approximately 220% more volatile than GILD relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 10% for BioHarvest Sciences Inc. Common Stock — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioHarvest Sciences Inc.

Common Stock (BHST) is pulling ahead at 98. 8% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, BHST leads at 128. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, SIGA Technologies, Inc.

(SIGA) trades at 2. 8x forward P/E versus 15. 7x for Gilead Sciences, Inc. — 12. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHST: 143. 3% to $10. 00.

In this comparison, SIGA (12.

7% yield), GILD (2. 4% yield) pay a dividend. BHST, NVAX, MRNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BHST (Basic Materials) and SIGA (Healthcare) and NVAX (Healthcare) and GILD (Healthcare) and MRNA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BHST is a small-cap high-growth stock; SIGA is a small-cap deep-value stock; NVAX is a small-cap high-growth stock; GILD is a mid-cap quality compounder stock; MRNA is a mid-cap quality compounder stock. SIGA, GILD pay a dividend while BHST, NVAX, MRNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.